Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas

<p>Supplementary Figure 2: Molecular features of A2.DR1 MHC-humanized gliomas. A. Verification of the CRISPR-Cas9-mediated functional KO of p53 and Nf1 in the A2.DR1 glioma cell line. B. Copy number variations (CNVs) in the A2.DR1 glioma cell line. C. Chromosomal distribution of CNVs D. Repres...

Volledige beschrijving

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Michael Kilian (16697663) (author)
Andere auteurs:	Mirco Friedrich (3721555) (author), Khwab Sanghvi (16697666) (author), Edward Green (3822586) (author), Stefan Pusch (14934437) (author), Daisuke Kawauchi (15115187) (author), Martin Löwer (133159) (author), Jana K. Sonner (16697669) (author), Christopher Krämer (16697672) (author), Julia Zaman (16697675) (author), Stefanie Jung (554730) (author), Michael O. Breckwoldt (16697678) (author), Gerald Willimsky (16697681) (author), Stefan B. Eichmüller (16697684) (author), Andreas von Deimling (15037904) (author), Wolfgang Wick (15018168) (author), Felix Sahm (15097382) (author), Michael Platten (15018165) (author), Lukas Bunse (16697687) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Immuno-oncology CNS Cancers Gliomas, Glioblastomas Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
door: Michael Kilian (16697663)
Gepubliceerd in: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
door: Michael Kilian (16697663)
Gepubliceerd in: (2025)

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
door: Maria Lozano-Rabella (15056515)
Gepubliceerd in: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
door: Maria Lozano-Rabella (15056515)
Gepubliceerd in: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
door: Maria Lozano-Rabella (15056515)
Gepubliceerd in: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
door: Isha Mondal (16721699)
Gepubliceerd in: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
door: Francesca Orzan (15055579)
Gepubliceerd in: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
door: Francesca Orzan (15055579)
Gepubliceerd in: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
door: Francesca Orzan (15055579)
Gepubliceerd in: (2025)

Supplementary Table S1 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
door: Mengjie Zhao (14845174)
Gepubliceerd in: (2025)

Supplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
door: Mengjie Zhao (14845174)
Gepubliceerd in: (2025)

Supplementary Table S4 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
door: Mengjie Zhao (14845174)
Gepubliceerd in: (2025)

Supplementary Table S5 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
door: Mengjie Zhao (14845174)
Gepubliceerd in: (2025)

Supplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
door: Mengjie Zhao (14845174)
Gepubliceerd in: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
door: Min Wu (14962986)
Gepubliceerd in: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
door: Min Wu (14962986)
Gepubliceerd in: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
door: Min Wu (14962986)
Gepubliceerd in: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
door: Min Wu (14962986)
Gepubliceerd in: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
door: Defne Bayik (14961098)
Gepubliceerd in: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
door: Qingsheng Xu (17078830)
Gepubliceerd in: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
door: Qingsheng Xu (17078830)
Gepubliceerd in: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
door: Bachchu Lal (17141949)
Gepubliceerd in: (2025)

Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
door: Reza Mirzaei (15306062)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_v64ttofar3nv52tobtgq5qk3oj